Results 151 to 160 of about 50,700 (273)

The Impact of Real‐Time Data Analytics on Infection Prevention and Control Practices in Ophthalmology: A Nursing Perspective on Patient Outcomes and Cost‐Effectiveness

Nursing &Health Sciences, Volume 28, Issue 2, June 2026.
ABSTRACT Ophthalmic surgeries pose infection risks. Traditional control methods rely on manual monitoring, creating a need for more precise, data‐driven nursing models. This study evaluated the effectiveness of real‐time data analysis in improving ophthalmic infection prevention and control outcomes.
Zhenhui Chen, Shengcheng Wu, Yi Zhou, Chun Tang   +3 more
wiley   +1 more source

Changes in Aqueous Humor Cytokine Profile Following Intravitreal Brolucizumab Injection

Clinical Ophthalmology
Varis Ruamviboonsuk,1,2 Wijak Kongwattananon,1,3 Natthaya Chuaypen4 1Department of Ophthalmology, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand; 2Medical Science Program, Department of Biochemistry, Faculty of Medicine ...
Ruamviboonsuk V, Kongwattananon W, Chuaypen N   +2 more
doaj  

Anti‐Apoptotic and Neurite‐Protective Nanomedicine Augments Embryonic Stem Cells‐Derived Retinal Ganglion Cell Transplantation in Glaucoma Recovery

Advanced Science, Volume 13, Issue 25, 4 May 2026.
Lithium‐epigallocatechin gallate nanoparticles (Li‐EGCG NPs) are co‐transplanted with embryonic stem cell‐derived retinal ganglion cells (ESC‐RGCs) to enhance cell survival and therapeutic efficacy in an acute pathological glaucomatous injury model. This synergistic approach protects RGC cells, preserves retinal structure and improves visual function ...
Moxin Chen, Xiaoyan Jiang, Yuanhui Wang, Zhaobin Luo, Yu Zhang, Siwei Liu, Rui Huang, Dandan Zhang, Zhimin Tang, Yahan Ju, Shaohui Pan, Ni Ni, Wei Feng, Yu Chen, Ping Gu   +14 more
wiley   +1 more source

A Cationic Block Co‐Polymer for Gene Delivery in the Posterior Segment of the Eye

Journal of Biomedical Materials Research Part A, Volume 114, Issue 5, May 2026.
ABSTRACT Diseases of the back of the eye such as neovascular age‐related macular degeneration (nAMD) are vision threatening and treatment is burdensome for patients, often requiring ocular injections every other month. Injection risks and logistics lower patient compliance; however, even patients receiving optimal treatment can deteriorate.
Amber Monteiro, Odunayo O. Mugisho, Antonio de Souza, Lina Liu, Yosra Agban, Priyanka Agarwal, Avik Shome, Ilva D. Rupenthal, Heather Sheardown   +8 more
wiley   +1 more source

Aptamer‐Functionalized Nanocarriers for Bone and Joint Diseases: Engineering Design Rules and Translational Roadmap

Small Science, Volume 6, Issue 5, May 2026.
Aptamer‐functionalized nanocarriers represent a versatile platform for targeted therapy in bone and joint diseases. This review presents five complementary design strategies: free aptamers for soluble targets, bispecific multivalent constructs for enhanced avidity, nanoparticle‐conjugated aptamers for selective tissue accumulation, aptamer‐based ...
Hamdi Al‐Azzani, Djandan Tadum Arthur Vithran, Syeda Sundas Batool, Malek Mohammed Ali Alshabi, Wenhu Zhou, Xiaoqiang Mao   +5 more
wiley   +1 more source

Decellularized Aged Bruch's Membrane Confers Unique Biochemical Cues to Retinal Pigment Epithelium for In Vitro Modeling of Age‐Related Macular Degeneration

Aging Cell, Volume 25, Issue 5, May 2026.
A Bruchs membrane (BrM) mimic based on aged decellularized BrM was developed and differentially expressed proteins in aged dECM‐BrM that may provide specific biochemical cues fundamental to model AMD in vitro were identified. RPE culture on aged dECM‐BrM developed certain AMD‐like features including reduced TEER and expression of drusen components ...
Blanca Molins, Mercedes Soledad Nabaes Jodar, Eliandre de Oliveira, Josep Maria Estanyol, Esther Peña, Jaione Bezunartea, María Hernández, Marc Figueras‐Roca, Alfredo Adan   +8 more
wiley   +1 more source

Real‐world outcomes of aflibercept 8 mg in patients previously treated for neovascular age‐related macular degeneration

Acta Ophthalmologica, Volume 104, Issue 3, Page 296-304, May 2026.
Abstract Purpose To evaluate visual, anatomical and safety outcomes of aflibercept 8 mg in previously treated patients with neovascular age‐related macular degeneration (nAMD). Methods This retrospective study included nAMD patients switched to aflibercept 8 mg from prior anti‐VEGF therapies at Sahlgrenska University Hospital between February 2024 and ...
Imadeddin Abu Ishkheidem, Esra Inci, Martin Breimer, Sofia Töyrä Silfverswärd, Madeleine Zetterberg, Marita Andersson Grönlund   +5 more
wiley   +1 more source

Neovascular age‐related macular degeneration without drusen

Acta Ophthalmologica, Volume 104, Issue 3, Page e300-e311, May 2026.
Abstract Purpose To describe the clinical characteristics and 1‐year follow‐up of patients with neovascular AMD (nAMD) without drusen in either eye. Methods This is a multicentre retrospective cohort study in three tertiary referral centres in The Netherlands. We included patients of 55 years or older with nAMD in one or both eyes, without the presence
Marc J. Sirks, Elon H. C. van Dijk, Husein Ghalayini, Somayeh Bazdar, WeiFeng Yu, Suzanne Yzer, José P. Martinez Ciriano, Reinier O. Schlingemann, Roselie M. H. Diederen, Camiel J. F. Boon   +9 more
wiley   +1 more source

Treatment of peripheral exudative hemorrhagic chorioretinopathy by intravitreal injections of ranibizumab

Clinical Ophthalmology, 2012
Kei Takayama,1 Tosio Enoki,1,2 Teruo Kojima,1,2 Sho Ishikawa,1 Masaru Takeuchi,11Department of Ophthalmology, National Defense Medical College, Saitama, Japan; 2Enoki Clinic, Saitama, JapanAbstract: Peripheral exudative hemorrhagic chorioretinopathy ...
Takayama K, Enoki T, Kojima T, Ishikawa S, Takeuchi M   +4 more
doaj  

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source